Cancer Family
Precursor Lymphoid Neoplasm
CI-CAN-00000327Explore in graph →
- NCIt
- C7055
Loading cancer entity…
Cancer Family
CI-CAN-00000327Explore in graph →
Variants & evidence
377 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| JAK3 M511I1 | ||||||||
| Tofacitinib | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID2977Mice transplanted with bone marrow progenitor cells expressing JAK3 mutants (including M511I) developed a long-latency transplantable T-ALL-like disease, characterized by an accumulation of immature C… (full text at CIViC) PMID 25193870 · Degryse et al., 2014 · Open in CIViC | civic |
| FGFR1 e15::e111 | ||||||||
| (oncogenic) | B Acute Lymphoblastic LeukemiaALIAS | Oncogenic | C | Supports Oncogenicity | 2 | submitted | EID1172528 yo with acute B-lymphoblastic leukemia. RNA seq showed KIF5B::FGFR1 fusion. Fusion was reported to be in-frame. The FGFR1 fusion and its protein expression were validated by Sanger sequencing and W… (full text at CIViC) PMID 38023217 · Zhang et al., 2023 · Open in CIViC | civic |
| KMT2A Rearrangement2 | ||||||||
| (diagnostic) | B Acute Lymphoblastic LeukemiaALIAS | Diagnostic | A | Supports Positive | 5 | submitted | EID8601B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged, is a well- defined subgroup in the current WHO classification of hematologic malignancies. PMID 27069254 · Arber et al., 2016 · Open in CIViC | civic |
| (prognostic) | Acute Lymphoblastic Leukemia | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID8600KMT2A, also called MLL (MIXED- LINEAGE-LEUKAEMIA) gene is mapped to chromosome band 11q23, a region of recurrent rearrangements in acute leukemias. Collectively, acquired abnormalities in the 11q23 re… (full text at CIViC) PMID 12057554 · Pui et al., 2002 · Open in CIViC | civic |
| KMT2A Fusion3 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A RearrangedALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID12473In this study, the authors used long-distance inverse PCR and sequencing to comprehensively analyze KMT2A (MLL) gene rearrangements in 2,345 acute leukemia patients, including those with B-lymphoblast… (full text at CIViC) PMID 28701730 · Meyer et al., 2018 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A RearrangedALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID12474In this publication, the authors conducted a comprehensive genomic analysis of 2,754 pediatric acute lymphoblastic leukemia (ALL) cases using integrated whole genome, exome, and transcriptome sequenci… (full text at CIViC) PMID 36050548 · Brady et al., 2022 · Open in CIViC | civic |
| 〃 | ||||||||
| ASNS Fusion1 | ||||||||
| Asparaginase | T Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | submitted | EID5926Fusion of the KMT2E promoter with the complete coding sequence of ASNS was observed in two relapsed ETP-ALL patients treated with l-asparaginase. The variant was shown to significantly increase ASNS e… (full text at CIViC) PMID 28069604 · Khater et al., 2017 · Open in CIViC | civic |
| ABL1 Fusion2 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 2 | accepted | EID9080This retrospective study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a BCR-ABL1-like (Ph-like) gene expression signature. RT-PCR … (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC | civic |
| (prognostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Prognostic | C | Supports Poor Outcome | 2 | accepted | EID9153This retrospective study reported the outcome of 24 patients with Ph-like acute lymphoblastic leukemia (Ph-like ALL) harboring ABL-class fusions who were treated with a combination of tyrosine kinase … (full text at CIViC) PMID 31434701 · Tanasi et al., 2019 · Open in CIViC | civic |
| BCL9 Fusion1 | ||||||||
| (prognostic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID12177This study was an international, multi-center retrospective analysis of 107 patients with MEF2D rearrangements, with information collected from 14 different regional study groups. The aim was to asses… (full text at CIViC) PMID 36309560 · Ohki et al., 2023 · Open in CIViC | civic |
| CSF1R Fusion3 | ||||||||
| Imatinib | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID9360This study describes a cohort of 24 patients with BCR-ABL1-like B-ALL and ABL-class kinase rearrangement exposed to TKI frontline or at relapse, who showed favorable MRD response and outcome. Specific… (full text at CIViC) PMID 31434701 · Tanasi et al., 2019 · Open in CIViC | civic |
| GW-2580 + ImatinibSubstitutes | Acute Lymphoblastic Leukemia | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID403Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase inhibitors Imatinib and GW-2580. PMID 24186003 · Lilljebjörn et al., 2014 · Open in CIViC | civic |
| Panobinostat | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | D | |||||
| MEF2D MEF2D Rearrangement1 | ||||||||
| (prognostic) | B Acute Lymphoblastic LeukemiaALIAS | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID8624MEF2D encodes myocyte enhancer factor 2D and is mapped to chromosome 1q21–22. It is expressed throughout B-cell differentiation and inactivation of Mef2c/d results in an arrest in B-lymphoid maturatio… (full text at CIViC) PMID 27824051 · Gu et al., 2016 · Open in CIViC | civic |
| TYK2 Fusion1 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | accepted | EID12810In this 2014 genomic profiling study of 1,725 patients with precursor B-cell acute lymphoblastic leukemia (B-ALL), the authors define the high-risk "Philadelphia chromosome-like" (Ph-like or BCR::ABL1… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| NOTCH1 F1592C1 | ||||||||
| Prednisone | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2852In a study of 157 patients under 18 years of age, with T-cell lymphoblastic leukemia (T-ALL), the frequency of NOTCH1 mutations was 52.2% (82/157). Patients with these mutations were associated with i… (full text at CIViC) PMID 16614245 · Breit et al., 2006 · Open in CIViC | civic |
| NOTCH1 F1592S1 | ||||||||
| Prednisone | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2821In a study of 157 patients under 18 years of age, with T-cell lymphoblastic leukemia (T-ALL), the frequency of NOTCH1 mutations was 52.2% (82/157). Patients with these mutations were associated with i… (full text at CIViC) PMID 16614245 · Breit et al., 2006 · Open in CIViC | civic |
| NOTCH1 L1574P1 | ||||||||
| Prednisone | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2691In a study of 157 patients under 18 years of age, with T-cell lymphoblastic leukemia (T-ALL), the frequency of NOTCH1 mutations was 52.2% (82/157). Patients with these mutations were associated with i… (full text at CIViC) PMID 16614245 · Breit et al., 2006 · Open in CIViC | civic |
| NOTCH1 L1574Q1 | ||||||||
| Prednisone | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2826In a study of 157 patients under 18 years of age, with T-cell lymphoblastic leukemia (T-ALL), the frequency of NOTCH1 mutations was 52.2% (82/157). Patients with these mutations were associated with i… (full text at CIViC) PMID 16614245 · Breit et al., 2006 · Open in CIViC | civic |
| NOTCH1 L1585R1 | ||||||||
| Prednisone | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2823In a study of 157 patients under 18 years of age, with T-cell lymphoblastic leukemia (T-ALL), the frequency of NOTCH1 mutations was 52.2% (82/157). Patients with these mutations were associated with i… (full text at CIViC) PMID 16614245 · Breit et al., 2006 · Open in CIViC | civic |
| NOTCH1 L1600P1 | ||||||||
| Prednisone | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2690In a study of 157 patients under 18 years of age, with T-cell lymphoblastic leukemia (T-ALL), the frequency of NOTCH1 mutations was 52.2% (82/157). Patients with these mutations were associated with i… (full text at CIViC) PMID 16614245 · Breit et al., 2006 · Open in CIViC | civic |
| NOTCH1 L1600Q1 | ||||||||
| Prednisone | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2822In a study of 157 patients under 18 years of age, with T-cell lymphoblastic leukemia (T-ALL), the frequency of NOTCH1 mutations was 52.2% (82/157). Patients with these mutations were associated with i… (full text at CIViC) PMID 16614245 · Breit et al., 2006 · Open in CIViC | civic |
| NOTCH1 Mutation2 | ||||||||
| Prednisone | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2692In a study of 157 patients under 18 years of age, with T-cell lymphoblastic leukemia (T-ALL), the frequency of NOTCH1 mutations was 52.2% (82/157). Patients with these mutations were associated with i… (full text at CIViC) PMID 16614245 · Breit et al., 2006 · Open in CIViC | civic |
| 〃 | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2693In a study of 157 patients under 18 years of age, with T-cell lymphoblastic leukemia (T-ALL), the frequency of NOTCH1 mutations was 52.2% (82/157). Patients with these mutations were associated with i… (full text at CIViC) PMID 16614245 · Breit et al., 2006 · Open in CIViC | civic |
| NOTCH1 V1577A1 | ||||||||
| Prednisone | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2824In a study of 157 patients under 18 years of age, with T-cell lymphoblastic leukemia (T-ALL), the frequency of NOTCH1 mutations was 52.2% (82/157). Patients with these mutations were associated with i… (full text at CIViC) PMID 16614245 · Breit et al., 2006 · Open in CIViC | civic |
| NOTCH1 V1577E1 | ||||||||
| Prednisone | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2825In a study of 157 patients under 18 years of age, with T-cell lymphoblastic leukemia (T-ALL), the frequency of NOTCH1 mutations was 52.2% (82/157). Patients with these mutations were associated with i… (full text at CIViC) PMID 16614245 · Breit et al., 2006 · Open in CIViC | civic |
| NT5C2 D407A2 | ||||||||
| Mercaptopurine + ThioguanineSubstitutes | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 4 | accepted | EID632CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 D407A mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C… (full text at CIViC) PMID 23377281 · Tzoneva et al., 2013 · Open in CIViC | civic |
| Arabinosylguanine + NelarabineSubstitutes | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | D | Does Not Support Resistance | 4 | accepted | EID635CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine… (full text at CIViC) PMID 23377281 · Tzoneva et al., 2013 · Open in CIViC | |
| NT5C2 K359Q3 | ||||||||
| (prognostic) | Acute Lymphoblastic Leukemia | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID667The K359Q somatic mutation was significantly correlated with early disease recurrence and relapse in 103 T-cell ALL regardless of treatment course. The data was obtained from Berlin Frankfurt Münster … (full text at CIViC) PMID 23377281 · Tzoneva et al., 2013 · Open in CIViC | civic |
| Arabinosylguanine + NelarabineSubstitutes | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | D | Does Not Support Resistance | 4 | accepted | EID636CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine… (full text at CIViC) PMID 23377281 · Tzoneva et al., 2013 · Open in CIViC | civic |
| Mercaptopurine + ThioguanineSubstitutes | ||||||||
| NT5C2 Mutation1 | ||||||||
| (prognostic) | Childhood Acute Lymphoblastic LeukemiaALIAS | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID7818Within a cohort of 71 pediatric B-ALL relapse cases, all 7 patients with NT5C2 mutations detected at relapse demonstrated early relapse (<36 months from initial diagnosis) with a median time to relaps… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| NT5C2 R238W4 | ||||||||
| (prognostic) | Childhood Acute Lymphoblastic LeukemiaALIAS | Prognostic | C | Supports Poor Outcome | 2 | accepted | EID786371 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed 3 early relapse cases with NT5C2 R238W enrich… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| Cytarabine + Doxorubicin + Gemcitabine + PrednisoloneSubstitutes | Childhood Acute Lymphoblastic LeukemiaALIAS | Predictive | D | Does Not Support Resistance | 4 | accepted | EID7816Overexpression of NT5C2 R238W in Reh cells resulted in no change in response to cytarabine, gemcitabine, doxorubicin or prednisolone versus wildtype or GFP controls as indicated by similar apoptosis. PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| NT5C2 R367Q6 | ||||||||
| Cytarabine + Doxorubicin + Gemcitabine + PrednisoloneSubstitutes | Childhood Acute Lymphoblastic LeukemiaALIAS | Predictive | D | Does Not Support Resistance | 4 | accepted | EID7815Lentiviral mediated overexpression of NT5C2 R367Q in Reh cells resulted in no change in apoptosis after exposure to cytarabine, gemcitabine, doxorubicin, or prednisolone compared to wildtype NT5C2 ove… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| Mercaptopurine + ThioguanineSubstitutes | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 4 | accepted | EID630CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 R367Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C… (full text at CIViC) PMID 23377281 · | |
| NT5C2 S445F3 | ||||||||
| (prognostic) | Childhood Acute Lymphoblastic LeukemiaALIAS | Prognostic | C | Supports Poor Outcome | 2 | accepted | EID786471 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed an early relapse case with NT5C2 S445F enrich… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| Cytarabine + Doxorubicin + Gemcitabine + PrednisoloneSubstitutes | Childhood Acute Lymphoblastic LeukemiaALIAS | Predictive | D | Does Not Support Resistance | 4 | accepted | EID7817Overexpression of NT5C2 S445F in Reh cells resulted in no change in response to cytarabine, gemcitabine, doxorubicin or prednisolone versus wildtype or GFP controls as indicated by similar apoptosis. PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| NUDT15 Inactivating Mutation1 | ||||||||
| Azathioprine + Mercaptopurine + ThioguanineSubstitutes | Childhood Acute Lymphoblastic LeukemiaALIAS | Predictive | B | Supports Adverse Response | 4 | submitted | EID7794Patients from three (Guatemala, Singapore and Japan) separate cohorts harboring NUDT15 loss of function mutations displayed intolerance to Thiopurine treatment (p=0.021, 2.1e-5, & 0.0054). Patients wi… (full text at CIViC) PMID 26878724 · Moriyama et al., 2016 · Open in CIViC | civic |
| ABL1 Fusion2 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 2 | accepted | EID9079This study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a BCR-ABL1-like (Ph-like) gene expression signature. RT-PCR or RNAseq perf… (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 1 | submitted | EID11616B-ALL cases with high-risk clinical features or suggestion of a kinase rearrangement were subjected to low density gene expression array to determine Ph-like status. 1 patient (12.1 years old) with a… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| ABL1 Fusion1 | ||||||||
| (prognostic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Prognostic | B | Supports Better Outcome | 3 | accepted | EID9148A multicenter, retrospective, cohort study that included 122 pediatric patients (aged 1-18 years) with newly diagnosed ABL-class fusion B-cell acute lymphocytic leukemia who had not received tyrosine-… (full text at CIViC) PMID 33357483 · den Boer et al., 2021 · Open in CIViC | civic |
Data updated 19 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A RearrangedALIAS |
| Diagnostic |
| B |
| Supports Positive |
| 4 |
| accepted |
EID12475In this publication, the diagnostic significance of KMT2A rearrangements in B-lymphoblastic leukemia/lymphoma (B-ALL) is explored. The study reveals that KMT2A fusions are not restricted to lymphoid l… (full text at CIViC) PMID 38686611 · Aypar et al., 2024 · Open in CIViC |
| civic |
| Supports Sensitivity Response |
| 3 |
| submitted |
EID9359In this study, 560 cases of B-ALL were analyzed by RNAseq, 22 (3.9%) of which (3.9%) demonstrated rearrangements of MEF2D at chromosome 1q21–22, encoding myocyte enhancer factor 2D, representing 15 of… (full text at CIViC) PMID 27824051 · Gu et al., 2016 · Open in CIViC |
| civic |
| civic |
| T Acute Lymphoblastic LeukemiaCURATED_BROADER |
| Predictive |
| D |
| Supports Resistance |
| 4 |
| accepted |
EID631CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 K359Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C… (full text at CIViC) PMID 23377281 · Tzoneva et al., 2013 · Open in CIViC |
| civic |
| Mercaptopurine + ThioguanineSubstitutes |
| B Lymphoblastic Leukemia/LymphomaCURATED_BROADER |
| Predictive |
| D |
| Supports Resistance |
| 2 |
| submitted |
EID8077Lentiviral-mediated overexpression of NT5C2 R238W (a relapse specific variant) in Reh cells resulted in resistance against thiopurines (mercaptopurine and thioguanine) compared to NT5C2 wildtype overe… (full text at CIViC) PMID 25962120 · Li et al., 2015 · Open in CIViC |
| civic |
| Mercaptopurine + ThioguanineSubstitutes | Childhood Acute Lymphoblastic LeukemiaALIAS | Predictive | D | Supports Resistance | 4 | accepted | EID7813Lentiviral-mediated overexpression of NT5C2 R238W in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| civic |
| Arabinosylguanine + NelarabineSubstitutes | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 4 | rejected | EID634CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (R367Q, R359Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine… (full text at CIViC) PMID 23377281 · Tzoneva et al., 2013 · Open in CIViC | civic |
| 〃 | T Acute Lymphoblastic LeukemiaCURATED_BROADER | Predictive | D | Does Not Support Resistance | 4 | accepted | EID633CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine… (full text at CIViC) PMID 23377281 · Tzoneva et al., 2013 · Open in CIViC | civic |
| Mercaptopurine + ThioguanineSubstitutes | Childhood Acute Lymphoblastic LeukemiaALIAS | Predictive | C | Supports Resistance | 2 | accepted | EID781271 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed an early relapse case with NT5C2 R367Q enrich… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| 〃 | Childhood Acute Lymphoblastic LeukemiaALIAS | Predictive | D | Supports Resistance | 4 | accepted | EID7862Lentiviral-mediated overexpression of NT5C2 R367Q in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC | civic |
| Mercaptopurine + ThioguanineSubstitutes |
| Childhood Acute Lymphoblastic LeukemiaALIAS |
| Predictive |
| D |
| Supports Resistance |
| 4 |
| accepted |
EID7814Lentiviral-mediated overexpression of NT5C2 S445F in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC |
| civic |